Abstract
The roles that the α and β isoforms of topoisomerase II (topo II) play in anticancer drug action were determined using MDA-VP etoposide-resistant human breast cancer cells and a newly constructed adenoviral vector containing the topo IIα gene (Ad-topo IIα). MDA-VP cells were more resistant to etoposide than to amsacrine and had more resistance to etoposide than did MDA-parental cells. MDA-VP cells also expressed lower topo IIα RNA and protein levels than parental cells but had comparable topo IIβ levels. After infection with Ad-topo IIα, topo IIα, RNA and protein levels increased significantly, as did the cells' sensitivity to etoposide. In contrast, topo IIβ levels remained constant with little alteration in the cells' sensitivity to amsacrine. Band-depletion immunoblotting assays indicated that topo IIα was depleted in etoposide-treated, Ad-topo IIα-transduced MDA-VP cells but not in amsacrine-treated cells. Topo IIβ was depleted in amsacrine-treated, Ad-topo IIα-MDA-VP cells, with little change in the topo IIα levels. These results suggest that topo IIα gene transfer does not alter topo IIβ expression and that enhanced sensitivity to etoposide is therefore secondary to change in topo IIα levels. These studies support the theory that etoposide preferentially targets topo IIα, while amsacrine targets topo IIβ. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Asano, T, An, T, Mayes, J, Zwelling, LA & Kleinerman, ES (1996). Transfection of human topoisomerase IIα gene into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem J, 319, 307–313.
Asano, T, An, T, Zwelling, LA, Takano, H, Fojo, AT & Kleinerman, ES (1996). Transfection of a human topoisomerase IIα gene into etoposide-resistant human breast tumor cells sensitizes the cell to etoposide. Oncol Res, 8, 101–110.
Austin, CA & Marsh, KL (1998). Eukaryotic DNA topoisomerase IIβ. Bioessays, 20, 215–226.
Austin, CA, Song, J, Patel, S & Fisher, LM (1993). Novel Hela topoisomerase is the IIβ isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta, 172, 283–291.
Dereuddre, S, Delaporte, C & Jacquemin-Sablon, A (1997). Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblast to topoisomerase II inhibitors. Cancer Res, 57, 4301–4308.
Errington, F, Willmore, E, Tilby, MJ, Li, L, Li, G, Baguley, BC & Austin, CA (1999). Murine transgenic cells lacking DNA topoisomerase IIb are resistant to Acridines and Mitoxantrone: Analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol, 56, 1309–1316.
Fan, D, Poste, G, Ruffoli, RR, Dong, Z, Seid, C, Earnest, LE, Campbell, TE, Clyne, RK, Beltran, PJ & Fidler, IJ (1994). Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzepine. Int J Oncol, 4, 789–798.
Ganapathi, R, Constantinou, A, Kamath, N, Dubyak, G, Grabowski, D & Krivacic, K (1996). Resistance to etoposide in human leukemia HL-60 cells: Reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol Pharmacol, 50, 243–248.
Herzog, CE, Holmes, KA, Tuschong, LM, Ganapathi, R & Zwelling, LA (1998). Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIα. Cancer Res, 58, 5298–5300.
Jenkins, JR, Ayton, P, Jones, T, Davies, SL, Simmons, DL, Harris, AL, Sheer, D & Hickson, ID (1992). Isolation of cDNA clones encoding the β isozyme of human DNA topoisomerase II and localization of the gene to chromosome 3q24. Nucleic Acids Res, 20, 5587–5592.
Koo, H-M, Gray-Goodrich, M, McWilliams, MJ, Jeffers, M, Vaigro-Wolff, A, Alvord, WG, Monks, A, Paull, KD, Pommier, Y & Woude, GFV (1999). The ras omcogene-mediated sensitization of human cells to toposiomerase II inhibitor-induced apoptosis. J Natl Cancer Inst, 91, 236–244.
Malonne, H & Atassi, G (1997). DNA topoisomerase targeting drugs: mechanism of action and perspectives. Anticancer Drugs, 8, 811–822.
Matsumoto, Y, Takano, H & Fojo, T (1997). Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res, 57, 5086–5092.
Tan, KB, Dorman, TE, Falls, KM, Chung, TD, Mirabell, CK, Crooke, ST & Mao, J (1992). Topoisomerase IIα and topoisomerase IIβ genes: Characterization and mapping to human chromosome 17 and 3, respectively. Cancer Res, 52, 231–234.
Tsai-Pflugfeder, M, Liu, LF, Liu, AA, Tewey, KM, Whang-Peng, J, Knutsen, T, Huebner, K, Croce, CM & Wang, JC (1988). Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21–22. Proc Natl Acad Sci USA, 85, 7177–7181.
Turley, H, Comley, M, Houlbrook, S, Nozaki, N, Kikuchi, A, Hickson, ID, Gatter, K & Harris, AL (1997). The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer, 75, 1340–1346.
Wang, JC (1996). DNA topoisomerase. Annu Rev Biochem, 65, 635–692.
Withoff, S, Vries, E, Keith, WN, Nienhuis, EF, Graaf, WTA, Uges, DRA & Mulder, NH (1996). Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4 . Br J Cancer, 74, 1869–1876.
Yang, X, Li, W, Prescott, ED, Burden, SJ & Wang, JC (2000). DNA topoisomerase IIβ and neural development. Science, 287, 131–134.
Zwelling, LA, Hinds, M, Chan, D, Mayers, J, Sie, KL, Parker, E, Silberman, L, Radcliffe, A, Beran, M & Blick, M (1989). Characterization of an amsacrine-resistant line of human leukemia cells. J Biol Chem, 264, 16411–16420.
Zhou, Z, Zwelling, LA, Kawakami, Y, An, T, Kobayahi, K, Herzog, C & Kleinerman, ES (1999). Adenovirus-mediated human topoisomerase IIα gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res, 59, 4618–4624.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Zhou, Z., Zwelling, L., Ganapathi, R. et al. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase II α gene transfer is independent of topoisomerase II β. Br J Cancer 85, 747–751 (2001). https://doi.org/10.1054/bjoc.2001.1966
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1966